A new pre-clinical mouse model could enable the study of HIV infection and the testing of cell therapies against the virus.
List view / Grid view
A critical stage of the SARS-CoV-2 replication process, known as frameshifting, could be targeted by new drugs, researchers say.
Scientists have developed PF74-like small molecules able to target the HIV-1 capsid protein, identifying four potent compounds.
Although a cure for HIV continues to elude scientists, strategies to control the virus and immunise people are developing at rapid pace. Here, Drug Target Review’s Victoria Rees discusses why researchers are focusing on antibodies as approaches to combat HIV and highlights recent findings from two pre-clinical studies into how…
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
Researchers have produced the first 3D image of the Mediator-bound pre-initiation complex, key in the regulation of gene expression.
A new therapeutic approach using the protein IL-21 could optimise the immune system, allowing it to combat HIV.
Researchers have suggested that dormant HIV can be eradicated from cells by attacking it based on its viral activities.
The natural language processing model trained using viral protein sequence data was able to predict promising targets for vaccines against HIV, influenza and coronaviruses.
Using CRISPR-Cas9, scientists have developed a new method for generating mouse lines for vaccine research in just a few weeks.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Using cryo-electron microscopy and site-specific mass spectrometry, researchers have mapped the glycans that shield HIV from the immune system.
In human cells, a drug candidate called PF-00835231 has demonstrated success at blocking the reproduction of SARS-CoV-2.